Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Ergonomic Training With or Without Structured Exercise in Oil Industry Workers With Chronic Musculoskeletal Pain

11 de noviembre de 2026 actualizado por: Doç.Dr.Ömer Şevgin, Uskudar University

Effect of Structured Exercise Added to Ergonomic Training on Pain, Pain-Related Disability and Quality of Life in Oil Industry Workers With Chronic Musculoskeletal Disorders: A Randomized Controlled Trial

This randomized controlled trial will investigate whether a 12-week structured exercise program added to ergonomic training reduces pain and pain-related disability and improves quality of life more than ergonomic training alone in oil industry workers with chronic musculoskeletal pain. Forty workers aged 25-50 years with musculoskeletal pain lasting at least 3 months will be randomly assigned to either ergonomic training plus exercise or ergonomic training only. Both groups will receive two 45-minute ergonomic training sessions specific to oil-field work (weeks 1 and 6) and a printed brochure. The exercise group will additionally perform a phased neuromuscular and resistance exercise program 3 days per week for 12 weeks, partly supervised at the worksite and partly home/worksite-based. Pain intensity (visual analogue scale), pain-related disability (Pain Disability Index), quality of life (SF-12), regional musculoskeletal symptoms (Extended Nordic Musculoskeletal Questionnaire) and sleep quality (Pittsburgh Sleep Quality Index) will be assessed by an assessor blinded to group allocation at baseline and after 12 weeks.

Descripción general del estudio

Descripción detallada

Background: Work-related musculoskeletal disorders are a leading cause of lost productivity and disability. Oil and gas installations combine heavy lifting, repetitive work, awkward postures, vibrating tools, prolonged standing and shift work; musculoskeletal symptom prevalence of 71-89% has been reported in this workforce. Multicomponent workplace programs combining exercise, ergonomics and education provide the most consistent benefit for pain and function, and ergonomic-educational interventions alone have reduced symptoms in oil and gas workers; however, no randomized controlled trial has evaluated the added value of exercise in this population.

Design: Prospective, assessor-blinded, two-arm, parallel-group, 1:1 randomized controlled trial conducted at a single oil industry facility. The study will be reported according to CONSORT and TIDieR. Participants will be randomized using a computer-generated list with variable block sizes (4 and 6); allocation will be concealed in sequentially numbered, opaque, sealed envelopes prepared by an investigator not involved in treatment or assessment.

Interventions: Both groups receive ergonomic training specific to oil-field work: two 45-minute face-to-face group sessions (8-12 workers) at weeks 1 and 6 covering musculoskeletal risk factors, NIOSH lifting principles, valve/flange and overhead work, hand-arm and whole-body vibration, prolonged standing and grated floors, control-room/office ergonomics, shift work and sleep hygiene, and a 5-minute micro-break routine, plus a printed brochure and micro-break card, with weekly reminder messages for 12 weeks. The exercise group additionally performs a 12-week structured program, 3 non-consecutive days per week, 45 minutes per session (36 sessions): weeks 1-2 fully supervised at the facility in groups of 4-6, weeks 3-12 one supervised and two home/worksite-based sessions per week supported by an illustrated brochure and guided video. Each session comprises warm-up and mobility (6 min), neuromuscular stabilization (12 min), resistance strengthening with elastic bands and light loads (14 min), job-specific functional exercise such as box lifting and carrying (6 min) and stretching (7 min). The program progresses through three phases (motor control and activation, weeks 1-4; endurance and strength, weeks 5-8; job-specific functional loading, weeks 9-12) with intensity targeted at Borg CR-10 4-6 and load progression by the 2-for-2 rule. The control group receives weekly ergonomic reminder messages and a telephone call every 2 weeks to equalize contact; the exercise program is offered to the control group after final assessment.

Outcomes: Assessments at baseline (T0) and at the end of the 12-week intervention (T1) by a physiotherapist blinded to group allocation. Primary outcome: pain intensity on a 0-10 cm visual analogue scale. Secondary outcomes: Pain Disability Index (0-70), SF-12 physical and mental component summaries, regional symptom prevalence on the Extended Nordic Musculoskeletal Questionnaire, and sleep quality on the Pittsburgh Sleep Quality Index (exploratory). Process measures: session adherence, Borg CR-10 and adverse events.

Sample size: A priori power analysis (G*Power 3.1; repeated-measures ANOVA, within-between interaction; f = 0.25, alpha = 0.05, power = 0.80, 2 groups, 2 measurements, correlation 0.50) indicated 34 participants; allowing for 15-20% attrition, 40 participants (20 per group) will be enrolled.

Analysis: Intention-to-treat with multiple imputation; per-protocol (adherence ≥70%) as sensitivity analysis. Primary outcome analyzed with 2 × 2 mixed-design repeated-measures ANOVA (group × time interaction) or ANCOVA on the week-12 score adjusted for baseline. Secondary continuous outcomes analyzed in the same way; Benjamini-Hochberg correction for secondary outcomes. Dichotomous Nordic data analyzed with McNemar and chi-square/Fisher tests. Effect sizes (partial eta squared, Cohen d) with 95% CIs, proportion exceeding the minimal clinically important difference and number needed to treat will be reported. Significance p < 0.05.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

25 años a 50 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age 25-50 years
  • Employed in the oil industry for at least 5 years
  • Musculoskeletal pain lasting at least 3 months, with symptoms in at least one body region in the last 12 months and the last 7 days on the Nordic Musculoskeletal Questionnaire
  • Pain intensity ≥3/10 on the visual analogue scale
  • Literate and able to communicate
  • Willing to participate and signing the informed consent form

Exclusion Criteria:

  • Spinal or extremity surgery or trauma within the last 6 months
  • Inflammatory rheumatic disease, radicular neurological signs (motor or reflex loss) or history of malignancy
  • Uncontrolled cardiovascular, pulmonary or neurological disease precluding exercise
  • Pregnancy
  • Physiotherapy/rehabilitation within the last 3 months or regular structured exercise ≥150 minutes per week
  • Planned job change or relocation during the study period

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Ergonomic training + structured exercise

Oil-field-specific ergonomic training (two 45-min sessions at weeks 1 and 6, brochure, weekly reminders) plus a 12-week phased neuromuscular and resistance exercise program, 3 days/week, 45 min/session, partly supervised at the worksite.

12 weeks, 3 non-consecutive days/week, 45 min/session (36 sessions). Weeks 1-2 fully supervised by a physiotherapist at the facility (groups of 4-6); weeks 3-12 one supervised + two home/worksite-based sessions per week with illustrated brochure and guided video. Three phases: motor control/activation (weeks 1-4, body weight and light bands), endurance/strength (weeks 5-8, medium bands, 5-8 kg), job-specific functional loading (weeks 9-12, heavy bands, 8-12 kg). Intensity Borg CR-10 4-6; progression by 2-for-2 rule; pain rule ≤3/10 during exercise returning to baseline within 24 h.

Comparador activo: Ergonomic training only (active control)

The same oil-field-specific ergonomic training (two 45-min sessions at weeks 1 and 6, brochure, weekly reminders) and a telephone call every 2 weeks for contact equalization; no exercise program during the study. The exercise program is offered after final assessment.

12 weeks, 3 non-consecutive days/week, 45 min/session (36 sessions). Weeks 1-2 fully supervised by a physiotherapist at the facility (groups of 4-6); weeks 3-12 one supervised + two home/worksite-based sessions per week with illustrated brochure and guided video. Three phases: motor control/activation (weeks 1-4, body weight and light bands), endurance/strength (weeks 5-8, medium bands, 5-8 kg), job-specific functional loading (weeks 9-12, heavy bands, 8-12 kg). Intensity Borg CR-10 4-6; progression by 2-for-2 rule; pain rule ≤3/10 during exercise returning to baseline within 24 h.

Two 45-minute face-to-face group sessions (8-12 workers) at weeks 1 and 6 delivered by a physiotherapist (short presentation, practical demonstration and teach-back, discussion). Content: oil-field musculoskeletal risk factors; NIOSH lifting principles; valve/flange and overhead work; vibrating tools and hand-arm vibration; prolonged standing, grated floors and stairs; vehicle/cabin and whole-body vibration; control-room/office ergonomics; shift schedules and sleep hygiene; 5-minute micro-break routine. Printed brochure and micro-break card; weekly reminder messages for 12 weeks.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in pain intensity (Visual Analogue Scale)
Periodo de tiempo: Baseline, Week 12

Average pain over the past week marked on a 10 cm horizontal line (0 = no pain, 10 = worst imaginable pain), measured in cm. Lower scores indicate less pain. Minimal clinically important difference ≥2 cm or ≥30%.

Baseline, Week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in pain-related disability (Pain Disability Index)
Periodo de tiempo: Baseline, Week 12

7 items (family/home responsibilities, recreation, social activity, occupation, sexual behavior, self-care, life-support activity) each rated 0-10; total 0-70, higher scores indicate greater disability. Turkish version validated.

Baseline, Week 12
Change in health-related quality of life (SF-12)
Periodo de tiempo: Baseline, Week 12

Physical Component Summary (PCS) and Mental Component Summary (MCS) scores, each 0-100; higher scores indicate better quality of life. Turkish version validated.

Baseline, Week 12
Change in regional musculoskeletal symptom prevalence (Extended Nordic Musculoskeletal Questionnaire)
Periodo de tiempo: Baseline, Week 12

Presence of symptoms (yes/no) in the last 7 days and last 12 months and activity limitation in nine body regions (neck, shoulders, upper back, lower back, elbows, wrists/hands, hips/thighs, knees, ankles/feet). Turkish version validated.

Baseline, Week 12
Change in sleep quality (Pittsburgh Sleep Quality Index) - exploratory
Periodo de tiempo: Baseline, Week 12

Seven component scores (0-3) summed to a global score 0-21; scores >5 indicate poor sleep quality. Turkish version validated.

Baseline, Week 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: Sedat Kartal, Üsküdar University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de diciembre de 2026

Finalización primaria (Estimado)

20 de mayo de 2027

Finalización del estudio (Estimado)

20 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

11 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

De-identified individual participant data may be made available from the principal investigator upon reasonable request after publication of the main results.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir